388 related articles for article (PubMed ID: 25254565)
1. Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer.
Sardain H; Lavoué V; Laviolle B; Henno S; Foucher F; Levêque J
Int J Gynecol Cancer; 2014 Nov; 24(9):1679-85. PubMed ID: 25254565
[TBL] [Abstract][Full Text] [Related]
2. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.
Chiantera V; Rossi M; De Iaco P; Koehler C; Marnitz S; Ferrandina G; Legge F; Parazzini F; Scambia G; Schneider A; Vercellino GF
Int J Gynecol Cancer; 2014 Jun; 24(5):916-22. PubMed ID: 24442006
[TBL] [Abstract][Full Text] [Related]
3. Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico.
Terán-Porcayo MA; Zeichner-Gancz I; del-Castillo RA; Beltrán-Ortega A; Solorza-Luna G
Med Oncol; 2006; 23(2):219-23. PubMed ID: 16720922
[TBL] [Abstract][Full Text] [Related]
4. (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy.
Höckel M; Horn LC; Einenkel J
Gynecol Oncol; 2012 Nov; 127(2):297-302. PubMed ID: 22864112
[TBL] [Abstract][Full Text] [Related]
5. Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival.
Kasuya G; Ogawa K; Iraha S; Nagai Y; Hirakawa M; Toita T; Kakinohana Y; Kudaka W; Inamine M; Ariga T; Aoki Y; Murayama S
Anticancer Res; 2013 May; 33(5):2199-204. PubMed ID: 23645776
[TBL] [Abstract][Full Text] [Related]
6. Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer?
Baiocchi G; Guimaraes GC; Faloppa CC; Kumagai LY; Oliveira RA; Begnami MD; Soares FA; Lopes A
Ann Surg Oncol; 2013 May; 20(5):1694-700. PubMed ID: 23212765
[TBL] [Abstract][Full Text] [Related]
7. Indications for primary and secondary exenterations in patients with cervical cancer.
Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A
Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276
[TBL] [Abstract][Full Text] [Related]
8. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
[TBL] [Abstract][Full Text] [Related]
9. Total pelvic exenteration for primary and recurrent malignancies.
Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH
World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer.
Fu JH; Gao Z; Ren CC; Shi YG
Asian Pac J Cancer Prev; 2013; 14(4):2377-81. PubMed ID: 23725144
[TBL] [Abstract][Full Text] [Related]
11. Pelvic exenteration for adenocarcinoma of the uterine cervix.
Crozier M; Morris M; Levenback C; Lucas KR; Atkinson EN; Wharton JT
Gynecol Oncol; 1995 Jul; 58(1):74-8. PubMed ID: 7789894
[TBL] [Abstract][Full Text] [Related]
12. [Isolated pelvic recurrences of cervical carcinoma treated with salvage chemoradiotherapy].
Besson N; Touboul E; Daraï É; Lefranc JP; Monnier L; Schlienger M; Huguet F
Cancer Radiother; 2014 Mar; 18(2):83-8. PubMed ID: 24462252
[TBL] [Abstract][Full Text] [Related]
13. Pelvic exenteration in clear cell adenocarcinoma of the vagina and cervix.
Senekjian EK; Frey K; Herbst AL
Gynecol Oncol; 1989 Sep; 34(3):413-6. PubMed ID: 2767532
[TBL] [Abstract][Full Text] [Related]
14. [High-dose intracavitary brachytherapy of a recurrent cervical cancer following surgery].
Kumagaya H; Ito H; Hashimoto S
Gan No Rinsho; 1990 Jan; 36(1):51-6. PubMed ID: 2299791
[TBL] [Abstract][Full Text] [Related]
15. Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?
Backes FJ; Billingsley CC; Martin DD; Tierney BJ; Eisenhauer EL; Cohn DE; O'Malley DM; Salani R; Copeland LJ; Fowler JM
Gynecol Oncol; 2014 Oct; 135(1):95-9. PubMed ID: 25084510
[TBL] [Abstract][Full Text] [Related]
16. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca--a single institution's experience over 16 years.
Tan KK; Pal S; Lee PJ; Rodwell L; Solomon MJ
Colorectal Dis; 2013; 15(10):1227-31. PubMed ID: 23714581
[TBL] [Abstract][Full Text] [Related]
17. Pelvic Exenterations for Advanced and Recurrent Endometrial Cancer: Clinical Outcomes of 40 Patients.
Schmidt AM; Imesch P; Fink D; Egger H
Int J Gynecol Cancer; 2016 May; 26(4):716-21. PubMed ID: 26937752
[TBL] [Abstract][Full Text] [Related]
18. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
19. Postoperative radiotherapy in early stage carcinoma of the uterine cervix: treatment results and prognostic factors.
Yeh SA; Wan Leung S; Wang CJ; Chen HC
Gynecol Oncol; 1999 Jan; 72(1):10-5. PubMed ID: 9889023
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
